Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.13 USD
8.31 M USD
65.49 M USD
68.07 M
About Protalix BioTherapeutics, Inc. (DE)
Sector
CEO
Dror Bashan
Headquarters
Hackensack
Website
Founded
1993
FIGI
BBG000JW08N5
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
mid term +15,000%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company o
$PLX - Inv SHS opportunity (EC tomorrow, BLA approval Apr27)Trigger above 5.5 (To the next resistance 5.8).
Very risky as well as catalysts opportunity movement.
Not recommended to buy or Sell PLX stocks!
Ready For A PopSteady accumulation over the last few weeks - looking ready to run with fundamentals catalysts of PDUFA and final Phase 3 data readout for PRX-102 in April
PLX Releases Phase 3 Trial Data tomorrow at 1:24 pm ESTPlease don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
$PLX - "Buy on rumor sell on news"?, Yet, BLA and BRIGHT aheadProtalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended
$PLX - One of my faves, Creating Positive MomentumPLX Could Claim Substantial Global Market Share In Fabry Disease.
April 27, BLA approval opportunity.
Technically, resistances in rage, 4.87 and 5.2.
Support level 4.4-4.35.
Not recommended to buy or sell PLX stocks (Very risky).
Just an Idea.
$PLX - The most important year for PROTALIX Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PLX is 1.76 USD — it has increased by 1.15% in the past 24 hours. Watch Protalix BioTherapeutics, Inc. (DE) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Protalix BioTherapeutics, Inc. (DE) stocks are traded under the ticker PLX.
PLX stock has fallen by −3.30% compared to the previous week, the month change is a 6.67% rise, over the last year Protalix BioTherapeutics, Inc. (DE) has showed a 0.57% increase.
We've gathered analysts' opinions on Protalix BioTherapeutics, Inc. (DE) future price: according to them, PLX price has a max estimate of 14.00 USD and a min estimate of 14.00 USD. Watch PLX chart and read a more detailed Protalix BioTherapeutics, Inc. (DE) stock forecast: see what analysts think of Protalix BioTherapeutics, Inc. (DE) and suggest that you do with its stocks.
PLX stock is 5.62% volatile and has beta coefficient of −0.55. Track Protalix BioTherapeutics, Inc. (DE) stock price on the chart and check out the list of the most volatile stocks — is Protalix BioTherapeutics, Inc. (DE) there?
Today Protalix BioTherapeutics, Inc. (DE) has the market capitalization of 129.59 M, it has decreased by −3.33% over the last week.
Yes, you can track Protalix BioTherapeutics, Inc. (DE) financials in yearly and quarterly reports right on TradingView.
Protalix BioTherapeutics, Inc. (DE) is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
PLX earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.06 USD resulting in a −50.00% surprise. The estimated earnings for the next quarter are 0.08 USD per share. See more details about Protalix BioTherapeutics, Inc. (DE) earnings.
Protalix BioTherapeutics, Inc. (DE) revenue for the last quarter amounts to 17.96 M USD, despite the estimated figure of 16.26 M USD. In the next quarter, revenue is expected to reach 18.21 M USD.
PLX net income for the last quarter is 3.24 M USD, while the quarter before that showed −2.20 M USD of net income which accounts for 246.89% change. Track more Protalix BioTherapeutics, Inc. (DE) financial stats to get the full picture.
No, PLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 208.00 employees. See our rating of the largest employees — is Protalix BioTherapeutics, Inc. (DE) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Protalix BioTherapeutics, Inc. (DE) EBITDA is −7.62 M USD, and current EBITDA margin is 17.79%. See more stats in Protalix BioTherapeutics, Inc. (DE) financial statements.
Like other stocks, PLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protalix BioTherapeutics, Inc. (DE) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Protalix BioTherapeutics, Inc. (DE) technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Protalix BioTherapeutics, Inc. (DE) stock shows the neutral signal. See more of Protalix BioTherapeutics, Inc. (DE) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.